News Features Skyrocketing Popularity Puts GLP-1 Agonists for Weight Loss on Cardiology’s Radar L.A. McKeown May 12, 2023
News Features FFR’s Future: Negative Trials Spur Debate Over Technology’s Role Michael O'Riordan December 23, 2021
News Features Funding the Future: How Industry Support for CV Trials Could Evolve Michael O'Riordan December 17, 2020
News Features COVID-19’s Enduring Impact on the Heart? Some Clues and Predictions Shelley Wood July 20, 2020
News Features COVID-19 Lockdown Inactivity May Spell Trouble for CVD Prevention Michael O'Riordan April 24, 2020
News Features ‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry Michael O'Riordan January 10, 2020
News Features ISCHEMIA Fracas: Amid Charges of Moving the Goalposts, Investigators Come Out Swinging Michael O'Riordan March 23, 2018
News Features Trajectory Unknown: How ORBITA Lands in Clinical Practice Still Up for Debate Michael O'Riordan November 27, 2017
News Features How Low Can You Go? Concerns Over Aggressive LDL Lowering Eased as PCSK9 Evidence Mounts Michael O'Riordan May 23, 2017
News Features Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond Shelley Wood December 30, 2016